The BRIDGE 53 is open to projects with preliminary data sets targeting inter alia the following research activities in the area of human therapeutics development.
If you are interested in the BRIDGE 53 and have any further questions regarding the application process and fields of funding, please contact the program coordinator.
You have identified a target candidate for a novel anti-infective, but conclusive evidence that the target is related to the proposed mechanism-of-action is missing.
You have developed a therapeutic antibody or small molecule against a first-in-class target to treat an infectious disease. Your antibody or compound has excellent on-target activity but its cellular effects in a physiological context are difficult to study.
You have generated a candidate for a novel broad-spectrum antibiotic with break-through therapeutic potential.
You have studied a small molecule tool compound to treat bacterial, viral or parasitic infections – but the potency is too low for definitive conclusions on the MoA.